-

01:59:17 PM

NUVL Stock News

NUVL - Nuvalent Inc

09/18/23 6:30 AM

Nasdaq : NUVL

conferencesclinical trial

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose-escalation data from its ongoing ALKOVE-1...

RHEA-AI

negative

09/05/23 6:30 AM

Nasdaq : NUVL

clinical trial

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the initiation of the Phase 2 portion of...

RHEA-AI

neutral

08/31/23 6:30 AM

Nasdaq : NUVL

conferences

Nuvalent to Participate in Upcoming September Investor Conferences

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in fireside chats during the...

RHEA-AI

neutral

08/10/23 6:30 AM

Nasdaq : NUVL

earnings

Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results

Nuvalent, Inc., a clinical-stage...

RHEA-AI

neutral

08/01/23 6:30 AM

Nasdaq : NUVL

conferences

Nuvalent to Participate in Upcoming August Investor Conferences

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in the following August...

RHEA-AI

neutral

05/24/23 6:30 AM

Nasdaq : NUVL

conferences

Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the...

RHEA-AI

neutral

05/11/23 6:30 AM

Nasdaq : NUVL

earningsclinical trial

Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results

Nuvalent, Inc., a clinical-stage...

RHEA-AI

neutral

04/19/23 6:30 AM

Nasdaq : NUVL

conferences

Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Stifel 2023 Virtual Targeted Oncology...

RHEA-AI

neutral

04/18/23 9:00 AM

Nasdaq : NUVL

clinical trial

Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data supporting the

RHEA-AI

neutral

03/23/23 6:30 AM

Nasdaq : NUVL

conferences

Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming poster presentation for the ongoing Phase 1/ 2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655. The poster will be archived on the Nuvalent website at...

RHEA-AI

neutral